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Information on the distribution and biology of the G-protein coupled receptor 4 (GPR4) in the brain 
is limited. It is currently thought that GPR4 couples to Gs proteins and may mediate central 
respiratory sensitivity to CO2. Using a knock-in mouse model, abundant GPR4 expression was 
detected in the cerebrovascular endothelium and neurones of dorsal raphe, retro-trapezoidal 
nucleus locus coeruleus and lateral septum. A similar distribution was confirmed using RNAscope in 
situ hybridisation. In HEK293 cells, overexpressing GPR4, it was highly constitutively active at neutral 
pH with little further increase in cAMP towards acidic pH. The GPR4 antagonist NE 52-QQ57 
effectively blocked GPR4-mediated cAMP accumulation (IC50 26.8 nM in HEK293 cells). In HUVEC 
which natively express GPR4, physiological acidification (pH 7.4-7.0) resulted in a cAMP increase by 
~55% which was completely prevented by 1 µM NE 52-QQ57. The main extracellular organic acid, L-
lactic acid (LL; 1- 10 mM), suppressed pH dependent activation of GPR4 in HEK293 and HUVEC cells, 
suggesting allosteric negative modulation. In unanaesthetised mice and rats, NE 52-QQ57 (20 mg/kg) 
reduced ventilatory response to 5 and 10% CO2. In anaesthetised rats, systemic administration of NE 
52-QQ57 (up to 20 mg/kg) had no effect on hemodynamics, cerebral blood flow and blood oxygen 
level dependent responses. Central administration of NE 52-QQ57 (1 mM) in vagotomised 
anaesthetised rats did not affect CO2-induced respiratory responses. Our results indicate that GPR4 
is expressed by multiple neuronal populations and endothelium and that its pH sensitivity is affected 
by level of expression and LL. NE 52-QQ57 blunts hypercapnic response to CO2 but this effect is 
absent under anaesthesia, possibly due to the inhibitory effect of LL on GPR4. 
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Introduction 
G-protein coupled receptors (GPCR) represent the largest family of drug targets and, for this reason, 
are widely medically exploited. Since the publication of the human genome, numerous new putative 
GPCRs were identified, many without any known endogenous ligands. Such “orphan” GPCR are often 
still known under the numbers they were given initially. GPR4 was de-orphanized in 2003 when it 
was found to be highly sensitive to changes in extracellular proton concentration(Ludwig et al., 
2003). Since that time, further proton-sensing GPCRs were identified, namely GPR65 and GPR68 
(http://www.guidetopharmacology.org).  
The cellular phenotype best established to be associated with strong GPR4 expression is 
endothelium in peripheral tissues as well as in the brain(Huang et al., 2007;Kim et al., 2005;Qiao et 
al., 2006;Sun et al., 2016;Wyder et al., 2011), this being consistent with the published transcriptome 
data(Zhang et al., 2016;Zhang et al., 2014). GPR4 activity in peripheral endothelial cells has been 
implicated in blood vessel formation(Dong et al., 2013), transmigration of monocytes(Huang et al., 
2007), responses to vascular endothelial growth factor(Wyder et al., 2011), vascular inflammation 
(Dong et al., 2013) and endothelial adhesiveness(Chen et al., 2011). Strong GPR4 expression was also 
shown in the kidney where it contributes to the control of acid-base balance(Brown & Wagner, 
2012). However, a recent study(Kumar et al., 2015) /id using in situ hybridization did not detect 
GPR4 in the cerebrovascular endothelium but, instead, almost exclusively in neurones of the 
brainstem retrotrapezoid nucleus (RTN), an area known to be important for central respiratory CO2 
chemosensitivity and control of breathing. At the same time, single cell PCR demonstrated strong 
GPR4 expression in the RTN neurones, in the adjacent C1 catecholaminergic neurones (which 
generate sympathetic tone;(Marina et al., 2013)) and in serotonergic raphe nucleus neurones(Kumar 
et al., 2015). That study also found in mice GPR4 deletion was associated with reduced respiratory 
CO2 sensitivity implicating GPR4 expressed at RTN neurones in central chemosensitivity to CO2. 
(Kumar et al., 2015) 
Thus, there is a certain controversy regarding localization of GPR4 in the brain, especially given 
recent direct demonstration of GPR4 expression in the capillaries of at least some parts of the 
brain(Sun et al., 2016) and images available in Allen brain atlas (http://www.brain-map.org/). 
 
It is well established that GPR4 is a Gs-coupled receptor which drives the activity of adenylate 
cyclase (AC, (Ludwig et al., 2003), although signaling via G13 and Gq/11 has also been documented 
(Tobo et al., 2007). However, the pH-sensitivity profile of GPR4-mediated cAMP accumulation may 
have a major effect on the role of this receptor in the body and brain specifically. It seems that this 
profile may be influenced by the methods used in different laboratories as it varies between the 
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published reports. Using transiently transfected HEK293 cells,(Ludwig et al., 2003) reported that 
GPR4 is inactive at pH>8.0, highly active at physiological pH (7.4) but further acidification to pH 6.8 
(which is a plausible range of physiological acidification) only results in a very small further activation 
of GPR4. In contrast, (Tobo et al., 2007) reported significant activation of GPR4 in response to 
acidification from 7.4 to 7.0, which is within the range of physiological pH changes. At the same time, 
relatively little is known about pH-dependency of GPR4 in cells which express it naturally (such as 
endothelium).  
 
Furthermore, protons which are detected by GPR4 are mainly derived from either carbonic acid or L-
lactic acid (LL). Considering known signaling properties of LL (Lauritzen et al., 2013;Tang et al., 
2014;Mosienko et al., 2015)we hypothesized that GPR4 could be additionally modulated by LL. This 
may have implications for various scenarios involving acidosis (respiratory vs metabolic). 
 
In this study, we evaluated the CNS expression profile of GPR4 using a cell lineage tracing mouse 
model, which enables identification of cells where the GPR4 locus is activated during ontogeny. To 
verify that the expression persists in mature animals we employed a highly sensitive RNAscope in 
situ hybridization technology. We then compared the pH-activation profile of GPR4 expressed using 
a recombinant approach in HEK293 cells with that of human vascular endothelium cells (HUVEC) 
which natively express GPR4 and tested the hypothesis that GPR4 activity can be modulated by LL. 
Next, we studied the pharmacological properties and physiological effects of a novel GPR4 
antagonist, NE 52-QQ57, developed by Novartis (compound 13 in (Velcicky et al., 2017)). This 
molecule is a centrally active GPR4 antagonist, effective after oral administration. Here, we confirm 
the high potency of NE 52-QQ57 as a GPR4 blocker and then evaluate its effects on central 
respiratory CO2 chemosensitivity in mice and rats. 
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METHODS 
 
1. Cloning of pCMV-GPR4-hIRES-EGFP 
The GPR4 PCR product was obtained from rat genomic DNA and cloned between BglII and HindIII 
sites in pCMV-hIRES-EGFP plasmid to allow bi-cistronic expression of EGFP as a marker of expression. 
Sequence of the GPR4 insert was confirmed. 
2. cAMP measurements in HEK293 cells transiently transfected with GPR4 and in HUVEC 
The GloSensor assay was used for cAMP measurements as previously described, with modifications 
(Binkowski et al., 2011). Transfection was optimised for the different two cell lines. HEK293 cells 
were plated in 96-well white polystyrene plates (Greiner Bio-One) in DMEM media (Gibco) 
supplemented with 10% FBS and 1% Penicillin/Streptomycin (Pen/Strep), at a density of 4x10
5
 
cells/ml to achieve ~70% confluence for transfection. After 20 hours, cells were transiently co-
transfected with the GloSensor cAMP plasmid GLO22F and pCMV-GPR4-hIRES-EGFP using Trans-IT 
293 (Mirus) according to the manufacturer’s protocol. Transfection efficiency was confirmed by 
fluorescent visualisation of EGFP. HUVEC were plated in 96-well white polystyrene plates in 
endothelial cell growth medium (Promocell) supplemented with 1% Pen/Strep. 2 x10
4
 cells were 
seeded per well. Since HUVEC are difficult to transduce using chemical transfectants, we generated 
an adenoviral vector for CMV-driven GLO22F expression and used it with multiplicity of infection of 
75. 
26 hours after the transfection, cells were incubated with 850μM beetle luciferin potassium salt 
(Promega) at pH 7.4 for 2 hours in the dark. Prior to adding drugs, media was changed to HBSS 
(Gibco) buffered with 20mM HEPES and titrated to the desired pH. Cells were incubated with NE 52-
QQ57 for 20 mins in a final well volume of 100μl. Luminescence measurements of cAMP 
accumulation were obtained using a Tecan microplate reader (Infinite M200 PRO).  
LL solutions were titrated to neutral pH (7.4) using NaOH and added to the media, while resultant pH 
was carefully controlled. A water soluble forskolin analogue NKH 477 (Santa Cruz Biotechnology, 0.1 
- 100μM) was used as a positive control to activate AC in a receptor-independent manner. 
Non-transfected HEK293 cells were unresponsive to pH changes such as used in these experiments. 
3. Assessment of the activity of NE 52-QQ57  
10mg of NE 52-QQ57 was first dissolved in 300μl DMSO and then further diluted into HBSS as 
required. In order to assess the efficacy of NE 52-QQ57 in blocking GPR4-mediated cAMP 
accumulation, experiments were performed at a range of pH (8.0 to 6.8). For estimation of IC50 of NE 
52-QQ57, tests were performed at pH 7.4. 
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4. Immunofluorescent localisation of GPR4 in the mouse brain 
In order to investigate the pattern of GPR4 expression in the brain, we generated a lineage tracing 
mouse model by expressing CRE recombinase (CreN) from the GPR4 locus. Homologous 
recombination of the GPR4-CreN targeting vector was achieved by transfection of the targeting 
vector into BALB/c mouse embryonic stem (ES) cells. Correctly targeted ES cells were selected by 
PCR and Southern blot. Targeted BALB/c ES cells were injected into C57Bl/6 host blastocysts and 
breeding of chimeric mice resulted in GPR4-CreN mice. These mice were then crossed with a 
reporter mouse harboring a floxed-STOP-EGFP cassette inserted into the Rosa26 locus. Removal of 
the STOP cassette by CreN-mediated loxP-recombination enables reporter expression in cells where 
CreN was present. Description of the GPR4 expression in peripheral tissues in this animal model is 
outside of the scope of the present paper. 
Male mice (postnatal day 15 or 30) were then deeply anaesthetised with isoflurane, and 
transcardially perfused with phosphate buffered saline (PBS), followed by 4% paraformaldehyde 
(PFA). Brains were removed and fixed in 4% PFA, and then transferred to 30% sucrose. For further 
storage, brains were kept in PBS containing 0.02% sodium azide. Sequential 40μm sections were cut 
using a freezing microtome. Prior to antibody staining sections were incubated with antigen retrieval 
reagent (Polysciences) following blocking solution containing 10% goat serum and 0.03% Triton X-
100. Free-floating sections were stained with antibodies diluted in PBS containing 1% goat serum 
and 0.03% Triton X-100. Anti-GFP (Invitrogen) and anti-TH (Santa Cruz) primary antibodies were 
applied in concentration of 1:400 and 1:50 respectively. For immunofluorescence, Alexa-488 and 
Alexa-594 (Thermo Fisher Scientific) secondary antibodies were used as recommended by the 
manufacturer. Fluorescent sections were cover slipped in Vectorshield
TM
, and GPR4 expression 
throughout the brain was assessed using a confocal microscope (Leica SP5).  
 
Fluorescent in situ hybridization (RNAscope) of GPR4 transcript in the mouse brain. 
A nine week old C57BL/6J mouse was euthanized by pentobarbital and immediately transcardially 
perfused with PBS, followed by 4% PFA. The brain was postfixed in 4% PFA overnight at 8°C, followed 
by cryoprotection in 20% Sucrose PBS at 8°C for 24 hours (all solutions RNAse free). Brain tissue was 
then embedded in O.C.T. matrix, and stored at -80°C until sectioning. 15μm Coronal sections were 
cut using a cryostat and mounted on superfrost plus microscope slides. Mounted sections were used 
for fluorescence in situ hybridization (FISH) using RNAscope multiplex fluorescent assay (Advanced 
Cell Diagnostics) according to manufacturer instructions. Fluorescent sections were cover slipped in 
Invitrogen ProlongTM Gold antifade reagent (Thermo Fischer Scientific). GPR4 transcript localization 
was assessed using a confocal microscope (Leica SP5).  
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5. Evaluation of NE 52-QQ57 effects in vivo  
All the experiments in the UK were performed in accordance with the European Commission 
Directive 2010/63/EU (European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes) and the UK Home Office (Scientific Procedures) Act 
(1986) with project approval from the Institutional Animal Care and Use Committees. Animal 
handling at Novartis was performed in accordance with animal protocols approved by the 
Kantonales Veterinäramt Basel (License number 2586/2015).  
 
5.1. Whole body plethysmography in rats and mice  
Respiratory rate (RR, breaths min
−1
) and tidal volume (VT, a.u) were measured by whole-body 
plethysmography in 10 male C57Bl/6J mice (Charles River, UK), 20-27g and 8 male Sprage-Dawley 
rats, 98-112g, (UCL Biological Services colony). In brief, animals were placed in a Plexiglas recording 
chamber (volume 400 ml for mice or 1l for rats) that was slightly pressurised by a continuous inflow 
of humidified room air (~1 L min-1). All experiments were performed at room temperature (22–
24°C). The animals were allowed ~ 15 min to acclimatise to the chamber environment at 
normoxia/normocapnia (21% O2, 79% N2, and <0.3% CO2). Normoxic hypercapnia was induced by 
switching to a pre-mixed gas containing 21% O2 with 5 or 10% CO2 and the balance made up by N2. 
The hypercapnic mixtures were applied for 5 min in succession. The measurements of RR and VT 
were taken during the last 2 min before exposure to hypercapnia and the last 2 minutes of each 
hypercapnic episode, when breathing stabilised. Hypercapnia-induced changes in the RR, VT, and 
minute ventilation (VE) (RR × VT) were averaged and expressed as mean ± SEM. Each animal 
underwent recordings with vehicle (25% v/v DMSO in 0.9% Saline; 200μl per mouse or 1ml per rat, 
i.p) and drug (NE-5-0057; 20mg kg-1, i.p) which were injected immediately before introduction into 
the plethysmography chamber, thus allowing at least 15 min for the effect to develop.  
 
5.2. Surgical procedures in rats 
Male Wistar rats, 8-9 weeks of age, were anaesthetised (induction 5% isoflurane, maintenance α-
chloralose 75mg kg
-1
, i.v.) and instrumented for blood pressure recording via femoral artery 
cannulation. The femoral vein was cannulated for administration of anaesthetic. The depth of 
anaesthesia was monitored by the stability of blood pressure and heart rate. The trachea was 
cannulated low in the neck with a 12 gauge cannula to maintain airway patency and/or for 
mechanical ventilation. Arterial blood gases were monitored using a blood gas analyser (Model 
380EX, Siemens, Dortmund, Germany) and maintained at PO2 ~120 mmHg, PCO2 35-40 mmHg, and 
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pH at 7.35–7.45. Body temperature was maintained at 37.0±0.5°C. At the end of the experiments, 
the animals were humanely killed by an overdose of pentobarbitone sodium (200mg kg
-1
, i.v.). 
 
5.3. Evaluation of the effects of NE 52-QQ57 on neurovascular coupling in rats 
The rat head was secured within the fMRI scanner with ear and incisor bars, after which mechanical 
ventilation was started with oxygen-enriched air using an MRI compatible ventilator (CWE). 
Neuromuscular blockade was induced by gallamine (10mg kg
-1
; i.v.) and supplemented as necessary. 
Imaging was performed using a 9.4T Agilent horizontal bore scanner (Agilent). A 72mm inner 
diameter volume coil was used for transmission (Rapid Biomedical) and signal was received using a 
4-channel array head coil (Rapid Biomedical). A flow sensitive alternating inversion recovery (FAIR) 
arterial spin labelling (ASL) MRI sequence was applied with a single shot gradient-echo echo planar 
imaging readout for simultaneous capture of cerebral blood flow (CBF) and T2* weighted blood 
oxygen level dependent (BOLD) data as described previously(Wells et al., 2015). The following 
sequence parameters were used: TR=5000ms, TI=2000ms, matrix size = 64×64, FOV = 35mm × 
35mm, TE=10ms, single slice (slice thickness =2mm), inversion pulse bandwidth =20,000Hz(Christie 
et al., 2012). BOLD and CBF responses in the somatosensory cortex were triggered by electrical 
stimulation of the forepaw. FAIR images were continuously acquired for ~ 6 mins during a block 
design consisting of three periods of 60s “rest” followed by 60s forepaw stimulation (3Hz, 0.3ms 
pulse width, 1.5mA). Two baseline BOLD/CBF time-series measurements were acquired (~12mins 
total imaging time). NE 52-QQ57 (10-20mg kg
-1
; i.p.) or vehicle (25% DMSO in phosphate buffered 
saline; 1.5ml kg
-1
) was then administered and two further BOLD/CBF time-series measurements 
were repeated 15 mins after drug/vehicle administration. Vehicle injections were without any 
effects (data not shown).  
Data analysis: fMRI. BOLD signals were taken from the “control” images following the global 
inversion pulse. CBF and BOLD time-series data, before and after drug/vehicle, were extracted from 
a manually drawn ROI in the unilateral forepaw region of the somatosensory cortex. The ASL CBF 
time-series data were corrected for contamination of BOLD effects at the time-points that coincide 
with the start and end of the forepaw stimulus where the BOLD signal is most different between tag 
and control conditions. For each animal, the average CBF/ BOLD signal before and during forepaw 
stimulation was taken.  
To generate spatial maps of significant BOLD signal changes to forepaw stimulation, BOLD images 
were spatially smoothed (0.5mm FWHM Gaussian kernel), and first level analysis of each time-series 
using an on/off regressor derived from the applied forepaw stimulus paradigm (and convolved with 
the standard HRF (SPM)) was applied to generate a statistical map before and after NE 52-
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QQ57/vehicle administration. In order to visualise the BOLD activation maps to forepaw stimulation, 
a minimum threshold of p < 0.05 with family wise error correction with a cluster size of > 5 voxels 
was chosen. 
 
5.4. Evaluation of cardiorespiratory effects of NE 52-QQ57 in rats  
Peripheral Application 
With animals spontaneously breathing, the tracheal cannula was connected to an open-circuit gas 
delivery system that allowed control of the composition of the inspired gas mixture. Two stainless 
steel braided wires (Advent RM, Oxford, UK) were implanted into the diaphragm to record 
diaphragmatic EMG. The signal was amplified (10,000x), filtered (500– 1500Hz), rectified and 
smoothed (π = 50ms).  
After a 15 mins stabilization period following the preparative surgery, the animals were subjected to 
a hypercapnic challenge: CO2 concentration in the inspired gas mixture was increased to 10% for a 
period of 2 min. Following a 15 min recovery period, NE 52-QQ57 was administered (i.p.) at 10 min 
intervals to achieve cumulative doses of 5, 10 and 20mg kg
-1
. 10 min after the final dose was given, 
the hypercapnic challenge was repeated. 
Central Application 
Animals were transferred to a stereotaxic frame in the supine position. Mechanical ventilation was 
started using a positive pressure ventilator (Model 683; Harvard Apparatus) with a tidal volume of ~2 
ml and a ventilator rate similar to the normal respiratory frequency (~60 strokes min
-1
). 
Neuromuscular blockade was induced by gallamine (10mg kg
-1
; i.v.) and supplemented as necessary 
(1-2mg kg h
-1
). 
The ventral brainstem surface was exposed as described previously (Gourine et al., 2005). Briefly, 
superficial neck musculature was divided along the midline by blunt dissection and retracted with 3-
0 sutures. The trachea and oesophagus were tied, bisected rostral to the tracheal cannula and 
reflected rostrally. The longus capitis muscle was partially excised to expose the occipital bone. 
Using a dental drill with a fine round-head bur, the bone was carefully removed leaving the dura 
intact. Upon completion of all surgical preparation the dura was incised and reflected laterally to 
expose the ventral surface of the brainstem. Constant flow of CSF covered the brain surface and was 
wicked away with a small piece of tissue. Peripheral chemodenervation was performed, with both 
vagi and carotid sinus nerves sectioned bilaterally. Activity from the central cut end of the right 
phrenic nerve was recorded as an indicator of central respiratory drive. The signal was amplified 
(20,000x), filtered (500– 1500Hz), rectified and smoothed (π = 50ms).  
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After a 15 min stabilization period, the animals were subjected to a hypercapnic challenge; CO2 
concentration in the inspired gas mixture was increased to 10% for 2 min. Following a 15 min 
recovery period, the vehicle (10% DMSO in artificial cerebro-spinal fluid) was applied directly to the 
exposed ventral surface of the brainstem. A second hypercapnic challenge was applied after 10 min. 
This sequence was repeated following the topical application of NE 52-QQ57 (1mM) on the ventral 
surface of the brainstem. 
Data analysis 
Physiological variables were digitized using a Power 1401 interface (CED) and stored on a PC for 
offline processing using Spike 2 software (CED). Hypercapnia-induced changes in the respiratory 
rate, amplitude of phrenic nerve discharge or diaphragmatic EMG bursts, and neural minute 
ventilation (respiratory rate x burst amplitude) in control conditions, following application of the 
vehicle or GPR4 antagonist were compared with 2-way ANOVA. P values of < 0.05 were considered 
significant. Hemodynamic variables were averaged over 60 sec periods for 5 min after application of 
each dose of the GPR4 antagonist. The effects of GPR4 application on HR and BP were compared to a 
control period taken 5 min immediately preceding the injection of the first dose. An extra time point 
was taken 10 min after the application of the largest dose of NE 52-QQ57. 
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RESULTS 
GPR4 expression in the mouse brain 
Immunofluorescence in transgenic mice 
Mice in which CRE was knocked into the GPR4 locus were crossed with a ROSA-EGFP-reporter line to 
activate the dormant EGFP expression cassette. ROSA-reporter mice are considered to be the best 
model for ubiquitous expression in all cell types upon activation and have been extensively used for 
that purpose(Abe et al., 2013;Srinivas et al., 2001). Expression of the activate reporter EGFP was 
analysed throughout the whole brain using anti-GFP immunohistochemistry. It is acknowledged that 
the activation of the dormant EGFP transgene could occur at different stages of animal 
development, including the embryonic phase. Immunohistochemistry revealed very strong marker 
expression in cerebral blood vessels of all calibres with signal originating from the endothelial cells 
(Fig. 1A). The most prominent expression in non-vascular cells was detected in the dorsal raphe 
nucleus (Fig. 1B) and lateral septum (Fig. 1C-E). EGFP expression was also evident in area A6 (locus 
coeruleus), however, only a few EGFP-expressing neurones were found to be TH-positive, i.e. 
noradrenergic (Fig. 1F). Marker expression was undetectable in the C1 adrenergic cell group. 
Neuronal labelling was also detected in the RTN as reported previously(Kumar et al., 2015) (Fig. 
1G,H). As expected, GPR4-positive neurones in the RTN were TH-negative (Fig. 1H). However, these 
neurones were scarce and had much lower level of marker expression compared to the 
neighbouring endothelial cells or raphe nucleus neurones (Compare Fig. 1 panels G,H with B and C). 
Apart from these distinct nuclei, isolated EGFP-positive neurones were detected sporadically across 
the whole brain. These neurones were fairly large (20-35µm in diameter) with long and extensive 
processes but could not be identified as any known phenotype (Fig. 1I). 
 
RNAscope FISH 
RNAscope labelling results in punctate staining which is likely to reflect local foci of mRNA in the cells 
which express the relevant gene (Fig 1J-Q, see also high power images in the Supplement). Green 
puncta were detected in the same areas as in the knock-in mouse indicating that in a postnatal 
mouse neuronal expression persists in multiple locations, including RTN, raphe and lateral septum. 
Even though localisation of endothelium was rather difficult in the absence of an additional 
endothelial stain, on a number of images vascular structures were also clearly seen (green arrows in 
panels J,N, Q). Therefore, distribution of GPR4 revealed by FISH is qualitatively similar to that 
observed in the knock-in mouse. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Comparison of GPR4-mediated cAMP accumulation in transiently transfected HEK293 cells and in 
HUVEC which express GPR4 natively 
We initially verified that receptor-independent cAMP production triggered by the soluble forskolin 
analogue NKH 477 is pH independent within the physiologically relevant range (pH 8.0 - 6.8). As 
shown in Fig. 2A, 20 μM NKH 477 evoked similar effects across this pH range indicating that the 
assay was stable across the pH range, and that other factors, for example AC or phosphodiesterase 
activities, did not change significantly. Cell lines transfected with plasmids bearing strong promoters 
express transgenes at high level untypical for GPCR. Naïve HEK 293 cells do not respond to 
acidification with changes in cAMP (data not shown) consistent with the lack of GPR4 expression in 
this cell line(Atwood et al., 2011). We first expressed recombinant GPR4 from the rat using plasmids 
with a CMV promoter and found that acidification resulted in a robust increase in cAMP level (Fig 
2B). Strong activation occurred in the range between pH 8.0 and 7.4, while further acidification 
resulted in no further increase in cAMP levels. This profile closely resembles the one in the original 
report by(Ludwig et al., 2003) and suggests that GPR4 acts as a constitutive driver of cAMP 
production at neutral pH, but makes it hardly suitable for detection of physiological pH changes (7.4-
7.0). Of note, the level of cAMP accumulation evoked by GPR4 at neutral pH is comparable to that 
achievable using 20 μM of NHK 477 (data not shown). We hypothesised that such a shift of pH 
sensitivity towards the alkaline range is a result of the high level of GPR4 expression which is 
common when using transient expression and plasmids with a strong promoter. We therefore tested 
pH sensitivity of GPR4-expressing HEK 293 cells using lower concentrations of DNA. As suspected, 
using 100 times less DNA shifted pH sensitivity towards more acidic values, closer to the 
physiological range (Fig. 2B). 
 
However, it is extremely difficult to tune the level of the recombinant receptor expression to match 
the physiological levels. Therefore, we next used HUVEC, which express GPR4 natively and found 
that in these cells activation occurs mainly between pH 7.7 and 7.1 (Fig. 2C; see Supplement for 
additional statistical information for this and other datasets) which is closer to the feasible 
physiological range. At the same time, the potency of this signalling system in HUVEC appeared to be 
rather modest, since between pH 7.4 and 7.1 cAMP level only increased by ~50%. For reference, 
activation of Gs-coupled β-adrenoceptors with isoprenaline led to >400% increase in cAMP (Fig. 2D). 
 
NE 52-QQ57 effect on GPR4 in HEK 293 cells is pH dependent 
The effect of NE 52-QQ57 on proton-mediated cAMP accumulation in cells over-expressing GPR4 
was dependent on pH (Fig. 3A) and this dependence in the acidic range could be explained by 
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competition with protons. NE 52-QQ57 (100nM) was maximally effective at pH 7.7 but 
approximately equally effective at pH 8.0 and 7.4. At pH 7.1, the potency of NE 52-QQ57 was 
reduced and at pH 6.8 NE 52-QQ57 (100nM) was ineffective. At pH 7.4, NE 52-QQ57 acts as a highly 
potent antagonist of GPR4 mediated cAMP accumulation with IC50 of 26.8nM (Fig. 3B).  
 
LL inhibits GPR4-mediated pH dependent cAMP accumulation in HEK293 and HUVEC 
When LL was applied to GPR4-transfected HEK293 cells (DNA concentration 0.1 μg/μl) or to HUVECs 
at a range of pH values, it concentration-dependently inhibited the cAMP accumulation induced by 
acidosis (Fig. 4A,B). In HEK293 cells the effect was significant at 10mM LL, but in HUVEC, 1 and 10 of 
LL significantly inhibited the pH responsiveness (Fig 4B). NE 52-QQ57 (1 μM) antagonised GPR4-
mediated responses in HEK293 cells but its efficacy was reduced at acidic pH (7.1 and 6.8) 
presumably due to high level of activation of the over-expressed receptor (Fig 4A). In HUVECs, 1 μM 
of NE 52-QQ78 completely blocked GPR4-mediated cAMP responses at all pH levels tested (Fig 4B).  
 
Central effects of NE 52-QQ57 on CO2-induced respiratory responses in unanaesthetised mice and 
rats 
Minute ventilation (VE) which is the cumulative of RR and VT was not significantly affected at baseline 
by 20 mg/kg of NE-52-QQ57 in either rats (n=8) or mice (n=10). Relative to the vehicle (25% DMSO), 
NE-52-QQ57 significantly attenuated VE during hypercapnia at 5 and 10% CO2 in both species. For 
example, with 10% CO2 VE increased to 216±11 a.u. in the group treated with vehicle, but only to 164 
±18  a.u. in mice treated with NE-52-QQ57 ( p<0.001). Similarly, in rats at 10% CO2 VE increased to 
662±40 a.u. in the vehicle group, but to 568 ±22 a.u. in the treated group (p<0.001). Thus, in freely 
behaving mice and rats NE22-QQ57 blunted hypercapnic response to CO2. 
 
Evaluation of NE 52-QQ57 cardio-respiratory effects in anaesthetised rats 
In anaesthetised rats, hypercapnia (10% CO2 in the inspired air) increased respiratory rate from 77±9 
to 94±13 bursts/min (Fig. 6A), and this was not affected following systemic administration of NE 52-
QQ57 (20 mg kg
-1
; n=8, 76±9 to 95±12 bursts min
-1
; p=0.92). NE 52-QQ57 had no effect on CO2-
evoked increases in diaphragm EMG amplitude (0.25±0.03 to 0.33±0.04V cf. 0.25±0.02 to 
0.34±0.03V; p=0.94) and minute ventilation (19±3 to 32±7A.U cf. 20±3 to 33±6A.U; p=0.88). Systemic 
NE 52-QQ57 also had no effect on basal respiratory rate (Fig. 6B). To additionally ensure that NE 52-
QQ57 reaches the central GPR4 targets, the drug was then delivered directly on the ventral surface 
of the brainstem, where the RTN is located. Hypercapnia (10% CO2 in the inspired air) in 7 animals 
with denervated peripheral chemoreceptors increased respiratory frequency, phrenic nerve 
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amplitude and minute ventilation (Fig. 6C). Hypercapnia increased the respiratory rate from 18±6 to 
40±5 bursts min
-1
 following application of the vehicle on the ventral brainstem surface. CO2 had a 
similar effect in the presence of NE-52-QQ57 (1 mM) on the ventral brainstem surface (18±4 to 41±5 
bursts min
-1
; p=0.86, Fig. 6C). NE 52-QQ57 had no effect on other components of the hypercapnic 
respiratory response including increases in phrenic nerve burst amplitude (0.04±0.01 to 0.06±0.02V 
vs. 0.04±0.02 to 0.06±0.02V; p=0.92) and minute ventilation (11±4 to 34±8A.U vs. 11±2 to 33±7A.U; 
p=0.97). Direct application of NE 52-QQ57 to the ventral medulla had no effect on baseline 
respiratory activity (Fig. 6D). 
 
Evaluation of the NE 52-QQ57 effects on hemodynamics and neurovascular coupling 
Systemic administration of NE 52-QQ57 (up to 20 mg/kg i.p., n=7) did not affect heart rate and blood 
pressure in anaesthetised rats (Supplementary Figure 1). Neither did the drug affect CBF and BOLD 
response to somatosensory stimulation (electrical stimulation of the forepaw). There were no 
differences in the spatial extent and magnitude of the evoked BOLD signals.  
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Discussion 
We have investigated the signalling properties, CNS distribution and physiological role of GPR4 in the 
mechanisms of cardiorespiratory control. Previous work had established that, in peripheral tissues, 
GPR4 is prominently expressed in the endothelium of blood vessels(Huang et al., 2007;Kim et al., 
2005;Qiao et al., 2006;Wyder et al., 2011), where its deletion can cause major abnormalities(Yang et 
al., 2007). In the brain, presence of GPR4 was confirmed for vascular endothelium(Sun et al., 2016). 
In addition, transcriptome data unequivocally map GPR4 to endothelium with hardly any expression 
in other brain cell types, at least in front brain regions (Zhang et al., 2016;Zhang et al., 2014). 
Surprisingly, a recent study reported no GPR4 expression in the CNS blood vessels using in situ 
hybridisation. Instead single cell PCR detected GPR4 in neurones of a few key brainstem nuclei 
including the RTN (91% GPR4-positive neurones), catecholaminergic area C1 (83%) and serotonergic 
raphe nucleus (100%)(Kumar et al., 2015). Here we employed a GPR4-CRE reporter knock-in mouse 
where expression of CRE is driven by the endogenous locus of the GPR4 gene and leads to the 
expression of CRE in all cells in which GPR4 is expressed during ontogeny, allowing cell lineage 
tracing by crossing these mice with a reporter line where expression of EGFP can be induced by CRE. 
Given that CRE is driven by the endogenous locus of the GPR4, it is assumed that it obeys strictly the 
same rules as the actual transcript encoded by this locus. We found that the EGFP was highly and 
abundantly expressed in all types of cerebral blood vessels (Fig. 1 A,B,C,F,G,H). Labelled vascular 
cells were found to be mainly (if not exclusively) endotheliocytes, because the expression can be 
traced all the way down to the capillary level and up the walls of the larger vessels (arterioles and 
veins). In addition, prominent EGFP expression was also found in neurones of the dorsal raphe nuclei 
(Fig. 1B) this is consistent with the serotonergic phenotype expressing GPR4 according to(Kumar et 
al., 2015). Another area of strikingly high marker expression is the lateral septum (Fig. 1C) which was 
never reported before. The GPR4-CRE reporter approach leaves room for potential overestimation 
of the spread of the gene of interest because expression of GPR4-CRE and CRE-dependent activation 
of the reporter gene may occur during early stages of development, while in the adult the GPR4 
locus could be repressed in some of these cells. Therefore, we employed the recently introduced 
FISH technique and have obtained comparable results. RNAscope detection is extremely sensitive 
and the staining appears as puncta localised within the cell, rather than an evenly spread 
fluorescence (Fig 1 J-Q). FISH confirmed GPR4 expression by various neuronal populations around 
the brain, including RTN, raphe, A6 group (locus coeruleus) and lateral septum. Since these results 
were obtained from a mature mouse, they confirm that our findings in the knock-in model were not 
a result of embryonic activation of the GPR4 locus. Expression in endothelium could also be 
detected, although without counter-staining (which we could not perform), the blood vessels could 
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only be identified by their shape. Admittedly, the density of FISH signal in the endothelium was less 
than we expected from the lineage tracing study, suggesting some reduction in GPR4 level in the 
endothelium in the mature animals. Interestingly, both, raphe nucleus (Balaban, 2002;Deakin, 
1991;Graeff et al., 1996;Mosienko et al., 2012) and lateral septum(Albert & Walsh, 1982;Talishinsky 
& Rosen, 2012;Yadin et al., 1993) have been extensively implicated in control of anxiety and 
aggression. Our study justifies further exploration of potential role of GPR4 in these nuclei if GPR4 
protein presence in them in adult animals can be confirmed at protein level. It also points to the very 
likely role of GPR4 in regulation of brain endothelial function and signalling between endothelium 
and parenchyma which we postulated earlier(Paton et al., 2002). 
 
The pioneering study which for the first time established GPR4 as a proton sensitive receptor(Ludwig 
et al., 2003)reported that the intracellular coupling for this receptor occurs via AC and that its 
activation occurs mainly between alkaline (~8.0) and neutral (~7.3) pH. This “flat” profile in the 
physiological pH range (7.4-7.0) was also documented by(Tobo et al., 2007) making it difficult to 
envisage this receptor as a primary pH sensor in the brainstem, where pH is rather tightly controlled 
and kept within ~7.6-7.0. In this study we re-evaluated GPR4-mediated proton-activated cAMP 
production in two model cell systems: HEK293 cells transiently transfected to overexpress GPR4, and 
HUVEC cells which express GPR4 natively. We first confirmed that the assay is sufficiently stable 
across the relevant pH range, this being necessary in light of previous reports of pH sensitive species 
of AC (Anand-Srivastava & Johnson, 1980;Birnbaumer & Yang, 1974). In HEK293 cells, transfected 
with recombinant GPR4 (but not naïve HEK293), cAMP accumulation occurred in the alkaline range, 
between pH 8.0 and 7.4 (Fig 2B) with no further cAMP increase at acidic pH (6.8). This operational 
range would be hardly suitable for CO2 monitoring in the brain. In contrast, HUVEC cells had a 
radically different activation profile (Fig. 2C) whereby essentially all GPR4-mediated cAMP 
accumulation occurred between pH 7.4 and 7.1. This range compares well to previous findings in 
HUVEC(Wyder et al., 2011). We hypothesised that the alkaline-shifted operational range of GPR4 in 
HEK293 cells registered here and in several previous studies could be explained by the high receptor 
expression levels typical for transient expression experiments in cell lines. Indeed, by lowering 
concentration of the GPR4 expressing plasmid we obtained a profile which better resembled the 
activation curve in HUVEC (Fig. 2B and 2C).  
Therefore, as illustrated in Figure 7, relatively high GPR4 levels (as in overexpressing HEK293 cells) 
are likely to lead to high GPR4 activity at neutral pH 7.4. In the case of a neurone, this could make it 
more excitable and active at neutral pH. At the same time, such an activation profile would be 
unsuitable for the detection of the changes in pH within physiologically relevant range (e.g. 7.4 to 
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6.8). Lower level of expression (as exemplified by HUVEC) offers a mechanism for the detection of 
physiological acidification but the potency of this mechanism seems to be limited. cAMP in HUVEC 
only increased by ~ 50% (Fig. 2C), a rather modest effect when compared to that of a canonical 
activator of Gs signalling, the β2 adrenoceptor (Fig. 2D). Possibly, cAMP-independent signalling may 
be more important for the action of GPR4 (see introduction), this includes also slow, genomic 
mechanisms which only become relevant under chronic conditions, such as during tumour 
formation. 
Protons which can activate GPR4 are mainly derived from carbonic acid and LL, the two key tissue 
acids. Concentrations of LL in plasma and brain are highly dynamic, in most reports ranging between 
100 μM and 5 mM, and increasing to 10 mM under conditions of hypoxia, metabolic stress or severe 
exercise(Mosienko et al., 2015). We found that LL has, irrespective of the action of protons, an 
additional effect on GPR4. Both in HEK293 and HUVEC, LL reduced proton-mediated cAMP 
accumulation mediated by GPR4 (Fig. 4). This effect was evident at 1 mM and increased significantly 
with 10 mM of LL. We cannot completely exclude the possibility that high concentrations of LL (e.g. 
10 mM and above) might have effects unrelated to the signalling mechanism under study, for 
example via LL effects on energy production and/or mitochondrial redox state. Nevertheless, the 
data obtained suggest that LL at biologically relevant concentrations acts as a negative (possibly 
allosteric) modulator of GPR4-mediated signalling. The data also suggest that under physiological 
blood and brain LL concentration (usually ~1 mM), GPR4 is partially tonically inhibited by LL and its 
sensitivity to protons is lower than could be expected from in vitro assays.  
 
The recently published GPR4 blocker, NE 52-QQ57 (Velcicky et al., 2017), represents a promising 
new family of drugs, because GPR4 is one of the potential targets in cancer therapy (Castellone et 
al., 2011;Damaghi et al., 2013) and inflammatory responses(Chen et al., 2011;Dong et al., 2013). Our 
experiments confirm NE 52-QQ57 as a highly potent but pH-dependent inhibitor of GPR4-mediated 
cAMP accumulation with an IC50 of 26.8 nM at physiological pH (7.4) in HEK293 cells. It was less 
effective under acidic (pH 7.1- 6.8) or alkaline (pH 8) conditions but 1 μM of NE 52-QQ57 completely 
abrogated any pH dependent cAMP responses in HUVEC. However, clinical application of GPR4 
blockers would be problematic if these drugs had serious adverse effects on cardio-vascular and/or 
respiratory homeostasis.  
 
We investigated this issue in awake mice and rats. In unanaesthetised animals 20 mg/kg of NE 52-
QQ57 caused a small, but significant reduction in the ventilatory response to hypercapnia evoked by 
5 and 10% CO2. This effect is consistent with the phenotype of GPR4 knock-out mice(Kumar et al., 
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2015). With reference to the in vitro parts of our study, the findings in mice may be best described 
by the “low level of expression” scenario (Fig. 7), whereby GPR4 acts as a weak constitutive driver of 
cAMP with a small additional capacity to further elevate cAMP during physiological acidification. In 
anaesthetised rats, systemic peripheral administration of NE 52-QQ57 in doses of up to 20 mg kg
-1
 
had no effect on respiratory CO2 chemosensitivity (Fig. 5), resting arterial blood pressure and heart 
rate. Direct application of NE 52-QQ57 onto the ventral surface of the brainstem also did not affect 
cardio-respiratory homeostasis (Fig. 6). Neurovascular coupling in the somatosensory cortex 
(Supplementary Fig 1) was also fully preserved.  
One possible reason for the lack of NE 52-QQ57 effect on CO2 sensitivity under anesthesia is the 
inhibitory action of LL on GPR4 as demonstrated here (Fig 4). Indeed, some anaesthetics such as 
urethane can significantly increase LL concentration (Alfaro & Palacios, 1997), although we were 
unable to find similar evidence for chloralose which was used here. If, however LL is increased by the 
anaesthetic, it could mask the GPR4-mediated effects. At the same time, we know that the other 
mechanism of chemosensitivity which resides in astrocytes is fully functional under chloralose 
anaesthesia(Gourine et al., 2010). 
 
Altogether, NE 52-QQ57 has no serious detrimental effects on cardiovascular and respiratory 
systems in rodents, and this may be considered as encouraging news for further development of 
potential clinical applications of GPR4 antagonists. The recent demonstration of antinociceptive 
activity of NE 52-QQ57 highlights a potential avenue for exploration(Velcicky et al., 2017), as does 
the potential application of another GPR4 antagonist for treatment of myocardial infarction(Fukuda 
et al., 2016). Further promising applications involve cancer therapy(Justus et al., 2013;Wyder et al., 
2011;Yang et al., 2007), neuro-inflammation, or renal disease. The biological significance of GPR4 
expression in multiple neuronal populations requires further investigation, especially given the 
association of some of these nuclei with anxiety and responses to stress. 
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Figure legends  
 
Figure 1.  
GPR4 expression in the mouse brain  
A-I. Fluorescent immunohistochemistry of GPR4-CRE-STOP-EGFP mouse brain slices using antibodies 
against EGFP (anti-GFP) and TH (marker of catecholaminergic neurones). Unless indicated otherwise, 
scale bars are 50μm.  
A. GPR4 expression in blood vessels was prominent throughout the whole brain (see all panels).  
B. Strong and wide-spread GPR4 expression in dorsal raphe nucleus neurones. 
C. GPR4 expression in neurones of the lateral septum. 
D, E. Higher magnification images from areas indicated in panel C.  
F. In the locus coeruleus (A6 cell group) GPR4 expression was detected in neurones, some of which 
were TH-positive (yellow arrows) or TH-negative (white arrows). 
G. Ventral edge of the medulla oblongata at the level of RTN. A few RTN neurones could be detected 
in some sections. Less than 10 EGFP-positive cells per animal were found.  
H. Some of the sections at RTN level were double-stained for TH, but TH-positive cells were EGFP-
negative and probably belonged to the C1 cell group. 
I. Scattered neurones of unclear phenotype were sporadically detected throughout the whole brain. 
J-Q – Results of RNAscope FISH.  
J. A blood vessel, scale bar 10µm 
K. Dorsal raphe 
L. lateral septum 
M. Lateral septum, magnified from L, scale bar 10μm 
N. Locus cortuleus, boundaries highlighted by the dotted line  
O. C1 cell group 
P and Q: RTN 
Green arrows in N and Q – blood vessels 
aq – aqueduct; CC – corpus collosum; RTN – retrotrapezoid nucleus 
See Supplement for the large scale versions of some of the images. 
 
Figure 2. 
In vitro characterisation of GPR4 activity  
A. Increases in cAMP induced by a water-soluble forskolin analogue NKH 477 and detected using 
Glosensor assay are stable across the physiologically relevant pH range. 20μM NKH 477 was applied 
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to naïve HEK293 cells (not GPR4 transfected). Data represent mean ± s.e.m (n=4 of triplicates). 
Differences are not statistically significant (repeated measures one-way ANOVA).  
B. pH-dependent cAMP accumulation in GPR4 expressing HEK293 cells depends on the quantity of 
DNA used for transfection and by implication on the level of the expression of GPR4. Data represent 
mean ± s.e.m. for averages of triplicates (n=7 of triplicates for 0.1 μg/µl, n=3 of triplicates for 0.01 
and 0.001 µg/µl). High levels of expression shifts the activation curve towards the alkaline range. 
Activation profile with 0.001 µg/µl DNA leads a profile which resembles response of HUVEC (see 
panel 2C) which express GPR4 natively. 
C. cAMP accumulation in HUVEC at different pH. Increase in cAMP without NE 52-QQ57 at pH 7.1 
and 6.8 is statistically significant (n=6 of triplicates, repeated measures one-way ANOVA shows 
p<0.01) 
D. Concentration-response curve for cAMP production evoked using non-selective β-adrenoceptor 
agonist isoprenaline to illustrate that HUVEC cells can mount a robust cAMP response to a different 
Gs-coupled GPCR. Isoprenaline activates natively expressed β2 adrenoceptors in a concentration-
dependent manner (n=3 of triplicates). -∞ indicates zero concentration of the drug. 
 
Figure 3 
NE 52-QQ57 is a novel GPR4 antagonist working in a physiological range of pH 
A. NE 52-QQ57 (formula above the bar chart) inhibits GPR4-mediated cAMP accumulation but its 
potency depends on proton concentration (pH). Plotted are mean % changes ± s.e.m. (n=5 of 
triplicates) where % change is calculated as (with drug – baseline)/(baseline x 100) for every 
triplicate. Inhibition by NE 52-QQ57 becomes less effective as pH decreases. Significant differences 
are shown by repeated measures one-way ANOVA with Tukey’s multiple comparisons post hoc test 
(** - p < 0.01). 
B. Concentration-response curve for NE 52-QQ57 at pH 7.4. Calculated IC50 is 26.8 nM. Data 
represent mean ± s.e.m. of triplicates. Log -10 corresponds to zero concentration of the drug. 
 
 
Figure 4 
LL inhibits cAMP accumulation induced by acidosis in a concentration-dependent manner in (A) 
HEK293 and (B) HUVEC cells.  
All values are normalised to control at pH 8.0 for each triplicate measurement. Two-way repeated 
measures ANOVA revealed a significant effect of pH (p<0.0001) and LL (p<0.05) on cAMP levels in 
HEK293 cells. Post-hoc Sidak’s multiple comparisons test shows confirmed significant differences 
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between effects of 0 and 10mM LL (p< 0.05 at pH 7.4 and 6.8, p<0.01 at pH 7.1) and between 100 
µM and 10 mM (p<0.05), but the difference between 1 and 10mM LL was not significant (p=0.53 at 
pH 7.1, p=0.78 at pH 6.8). In HUVECs, the same analysis revealed a significant effect of pH (p<0.0001) 
and LL (p<0.05) and a significant interaction effect (p<0.001). The post-hoc test shows significant 
differences between 0 and 10mM (p<0.05 at pH 7.1, p<0.0001 at pH 6.8), between 100 µM and 10 
mM (p<0.05 at pH 7.1, p<0.0001 at pH 6.8), and between 100 µM and 1 mM (p<0.05 at pH 6.8). 
n=4-5 of triplicates for each data point in (A) and (B), apart from n=3 for 1μM NE 52-QQ57 curve in 
HUVEC. 1μM NE 52-QQ57 antagonises pH dependent activation of GPR4, the block is overcome at 
acidic pH in HEK293 cells. 
Figure 5 
NE 52-QQ57 blunts hypercapnic response to 5% and 10% CO2 in unanaesthetised mice (n=10) and 
rats (n=8). 
VT and VE measured at 5 and 10% CO2 were significantly reduced by NE 52-QQ57 (20mg/kg i.p.) 
relative to the vehicle group (25% DMSO).  
**p<0.01 and ****p<0.0001 vs. vehicle, repeated measurement two-way ANOVA followed by 
Sidak’s multiple comparisons test.  
 
Figure 6 
Peripheral or central administration of NE 52-QQ57 has no effect on CO2-induced respiratory 
responses. 
A. Averaged responses (left) and raw traces (right) to illustrate responses to hypercapnia after i.p. 
administration of NE 52-QQ57 (20mg/kg). Di – raw activity of the diaphragm, ʃDi – integrated activity 
of the diaphragm to illustrate respiration.  
B.  Effect of i.p. administration of NE 52-QQ57 (20 mg kg
-1
) on baseline diaphragmatic EMG activity.  
C. Responses to hypercapnia after topical application of NE 52-QQ57 (1mM) on the ventral surface 
of the medulla oblongata. NE 52-QQ57 had no effect on CO2-induced responses (two-way ANOVA). 
PN – activity of the phrenic nerve.  
D. Effect of direct application of NE 52-QQ57 (1mM) on the ventral surface of the medulla oblongata 
on baseline phrenic nerve activity. PN Rate – frequency of respiration measured from the ʃPN traces. 
 
Figure 7 
Schematic to illustrate the putative impact of GPR4 expression level on its function 
High level of expression (as exemplified by transiently transfected HEK293 cells) leads to production 
of copious amounts of cAMP at neutral pH (7.4) and makes the system insensitive to physiological 
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acidification. Low, natural level of expression, such as in HUVEC, reveals GPR4 mediated responses 
within the physiological window (7.4 - 6.8) but limits the potency of GPR4-mediated signaling via 
cAMP, making it unsuitable for fast and robust cellular responses. 
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Highlights 
 
1. The proton receptor GPR4 is expressed by multiple neuronal populations and brain 
endothelium.  
2. At low, physiological level of expression GPR4 is operational within physiological level of pH 
leading to a modest increase in cAMP. 
3. The GPR4 antagonist NE 52-QQ57 effectively blockS GPR4-mediated cAMP accumulation. 
4. The main extracellular organic acid, L-lactic acid, suppressed pH dependent activation of 
GPR4. 
5.  In unanaesthetised mice and rats, NE 52-QQ57 reduced ventilatory response to 5 and 10% 
CO2 but it was inefficient in anesthetized rats. 
